Peptides with protective activity against cell damage caused by particulate matter and uses thereof

Abstract

The present application relates to a peptide having protective activity against cell damage caused by particulate matter, and the use of the peptide.

Description

Technical Field

[0001] The present application relates to a peptide having protective activity against cell damage caused by particulate matter, and the use of the peptide. Background Art

[0002] Particulate matter refers to small, invisible particles of dust. Particulate matter is an air pollutant that includes sulfur dioxide, nitrogen oxides, lead, ozone, carbon monoxide, etc., which is produced in cars, factories, cooking processes, etc. and suspended in the atmosphere for a long time. Particles with a diameter of less than 50μm suspended in the atmosphere are called total suspended particles (TSP), and particles smaller than 10μm in these TSP are usually defined as particulate matter. Particulate matter is divided according to the diameter of the particles. Particles with a diameter of less than 10μm are named PM10, and particles with a diameter of less than 2.5μm are named PM2.5, also known as "fine particles" or "ultrafine particles."

[0003] Particulate matter contains carbon, organic hydrocarbons, nitrates, sulfates and harmful metal components, and is known to directly induce or aggravate respiratory diseases, cardiovascular diseases, eye diseases, cancer, skin diseases, headaches, etc. In addition, since the particle size of particulate matter is about one-fifth of the pores of the skin, when particulate matter penetrates into the skin, the protective film function of the outer layer of the skin is damaged and the skin becomes sensitive to irritation.

[0004] Polycyclic aromatic hydrocarbons (PAH) contained in particulate matter enter the skin through the hair follicles in the skin, increasing melanocytes and pigment spots, reducing collagen synthesis, and increasing collagen decomposition, thereby causing wrinkles, reducing skin elasticity and promoting skin aging. PAHs can penetrate into cells, bind to aromatic hydrocarbon receptors (AHR) that have already penetrated into cells, and be transported to the cell nucleus. The AHR transported to the cell nucleus forms a complex AHR / ARNT with the AHR nuclear transporter (ARNT), and the complex "AHR / ARNT" binds to the AHR response element (AHRE) on DNA, the dinucleotide kinase (DNT), and the aryl hydrocarbon receptor (AHR) on DNA. The DRE and XRE sequences combine to produce reactive oxygen species (ROS), or toxic substances are produced through enzymes such as CYP1A1, CYP1A2 and CYP1B1, thereby inducing cell damage and increasing the expression of various inflammatory mediators, causing dermatitis, pigment hyperplasia (chloasma, freckles, etc.) and wrinkles on the skin. Among them, microphthalmia-related transcription factor (Mitf) is a transcription factor related to melanin synthesis, and matrix metalloproteinase (MMP) is an enzyme related to wrinkle formation.

[0005] Prior art literature

[0006] Patent Literature

[0007] Korean Patent No.10-2065171 Summary of the invention

[0008] Technical issues

[0009] The present inventors have conducted research and worked on developing a peptide having an activity capable of preventing damage to cells when particulate matter comes into contact with body cells. As a result, it was experimentally demonstrated that the peptide developed by the present inventors has a cell protective activity by inhibiting the activation of AHR induced by particulate matter and simultaneously inhibiting the activity of cytochrome P450 induced by the activation of AHR, thereby completing the present invention.

[0010] Therefore, one aspect of the present invention provides a peptide having an activity effective in preventing cell damage induced by particulate matter.

[0011] Another aspect of the present invention provides a composition for preventing cell damage, which comprises the peptide having the above-mentioned activity as an active ingredient.

[0012] Still another aspect of the present invention provides a cosmetic composition for preventing skin cell damage, the composition comprising the peptide having the above-mentioned activity as an active ingredient.

[0013] Another aspect of the present invention provides a pharmaceutical composition for treating or preventing diseases caused by exposure to particulate matter, the composition comprising the peptide having the above-mentioned activity as an active ingredient.

[0014] Technical Solution

[0015] In order to achieve the above goals,

[0016] According to one aspect of the present invention, a peptide having the activity of preventing cell damage caused by particulate matter is provided, wherein the peptide consists of the amino acid sequence of SEQ ID NO: 1.

[0017] According to another aspect of the present invention, there is provided a composition for preventing cell damage caused by particulate matter, the composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0018] According to yet another aspect of the present invention, there is provided a cosmetic composition for preventing skin cell damage caused by particulate matter, the cosmetic composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0019] According to yet another aspect of the present invention, there is provided a pharmaceutical composition for treating or preventing a disease caused by particulate matter, the pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0020] Hereinafter, the present invention will be described in detail.

[0021] 1. Peptides and activity

[0022] According to one aspect of the present invention, a peptide consisting of the amino acid sequence of SEQ ID NO: 1 is provided.

[0023] As used herein, the term "peptide" refers to a linear molecule formed by amino acid residues linked together by peptide bonds.

[0024] The peptide of the present invention consisting of the amino acid sequence of SEQ ID NO: 1 can be used without modification, but on the other hand, the peptide can be a variant or fragment of amino acids with a different sequence formed by deletion, insertion, substitution or a combination thereof of amino acid residues within a range that does not affect the original activity of the peptide (e.g., the activity of protecting against cell damage caused by particulate matter).

[0025] The peptide of the present invention can be modified by phosphorylation, sulfation, acryloylation, glycosylation, methylation, farnesylation, etc. within the range that does not change the activity of the peptide.

[0026] The peptides of the present invention include peptides and variants thereof or active fragments thereof comprising an amino acid sequence substantially identical to the amino acid sequence of a peptide consisting of the amino acid sequence of SEQ ID NO: 1. A peptide comprising a substantially identical amino acid sequence refers to an amino acid sequence comprising an amino acid sequence having at least 75%, such as at least 80%, at least 90% or at least 95% sequence identity with the amino acid sequence of SEQ ID NO: 1. The peptide may also include additional sequences, such as targeting sequences, tags, labeled residues, or amino acids prepared for a specific purpose to increase the half-life or stability of the peptide.

[0027] The peptides of the present invention may have induced N-terminal and / or C-terminal modifications to select certain parts of the amino acid sequence and increase their activity. The stability of the peptides of the present invention can be significantly improved by N-terminal and / or C-terminal modifications, for example, when the peptide is administered in vivo, the half-life of the peptide can be extended. The term "stability" of a peptide refers not only to the in vivo stability for protecting the peptides of the present invention from in vivo protease attacks, but also to storage stability (e.g., storage stability at room temperature).

[0028] The N-terminal modification may be the binding of a protecting group selected from the group consisting of acetyl, fluorenylmethoxycarbonyl, formyl, palmitoyl, myristoyl, stearoyl and polyethylene glycol (PEG) to the N-terminal of the peptide.

[0029] The C-terminal modification may be the binding of a hydroxyl group (-OH), an amino group (-NH2), an azido group (-NHNH2), etc. to the C-terminal of the peptide, but is not limited thereto.

[0030] The peptides of the present invention can be prepared by various methods widely known in the art to which the present invention belongs. For example, the peptides of the present invention can be prepared using chemical synthesis methods known in the art, particularly solid phase synthesis techniques (Merrifield, J. Amer. Chem. Soc. 85: 2149-54 (1963); Stewart, et al., Solid Phase Peptide Synthesis, 2nd. ed., Pierce Chem. Co.: Rockford, 111 (1984)) or liquid phase synthesis techniques (US Patent No. 5,516,891).

[0031] The peptides of the present invention can effectively prevent cell damage caused by particulate matter.

[0032] Polycyclic aromatic hydrocarbons (PAH) contained in particulate matter can penetrate into cells, and the PAHs that penetrate into cells will bind to the aryl hydrocarbon receptor (AHR) and be transported to the cell nucleus. The AHR transported into the cell nucleus forms a complex AHR / ARNT with the AHR nuclear translocator (ARNT), and the complex "AHR / ARNT" binds to the AHR response element (AHRE), dinucleotide kinase (DNT) and mitochondria on DNA. The DRE and XRE sequences bind to the cytotoxic factor response element (DRE) and the xenobiotic response element (XRE) to generate reactive oxygen species (ROS) or increase the expression or activity of enzymes (such as CYP1A1, CYP1A2, and CYP1B1), thereby producing toxic substances that induce cell damage and increase the expression of various inflammatory mediators.

[0033] The peptide of the present invention significantly inhibits the nuclear translocation of the aryl hydrocarbon receptor (AHR) and the thereby increased cytochrome P450 activity in cells due to contact with particulate matter, thereby being able to prevent cell damage caused by particulate matter.

[0034] 2. Composition for preventing cell damage

[0035] According to another aspect of the present invention, there is provided a composition for preventing cell damage caused by particulate matter, the composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0036] In one embodiment, the cell damage can be skin cell damage, respiratory cell damage, or corneal cell damage.

[0037] In another embodiment, the peptide of the present invention may have the activity of inhibiting the activation of aryl hydrocarbon receptor (AHR). The inhibition of AHR activation by the peptide may be the inhibition of AHR translocation into the cell nucleus.

[0038] In another embodiment, the peptide of the present invention may have an activity of inhibiting cytochrome P450 activity. The inhibition of cytochrome P450 activity by the peptide may be inhibition of the activation or expression of cytochrome P450.

[0039] In another embodiment, the particulate matter may include polycyclic aromatic hydrocarbons (PAHs).

[0040] According to another aspect of the present invention, there is provided a cosmetic composition for preventing skin cell damage caused by particulate matter, the cosmetic composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0041] In the present invention, the damage of particulate matter to skin cells may include, for example, skin aging, increased skin wrinkles, impaired skin elasticity, impaired skin color, pigmentation hyperplasia, melasma, freckles, dry skin, skin inflammation, contact dermatitis, atopic dermatitis or psoriasis.

[0042] The cosmetic composition may be a composition for improving skin aging, increased skin wrinkles, impaired skin elasticity, impaired skin color, pigmentation hyperplasia, melasma, freckles, dry skin, skin inflammation, contact dermatitis, atopic dermatitis, or psoriasis.

[0043] The cosmetic composition of the present invention may comprise (i) a cosmetically effective amount of the above-mentioned peptide of the present invention; and (ii) a cosmetically acceptable carrier.

[0044] The term "cosmetically effective amount" refers to an amount sufficient for the composition of the present invention to achieve the effect of preventing skin cell damage caused by particulate matter.

[0045] The cosmetic composition of the present invention can be prepared according to any formulation commonly prepared in the art, for example, it can be formulated into a solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleanser, oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be formulated into a lotion, a nutrition lotion, a nutrition cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a mask (pack), a spray or a powder.

[0046] When the preparation of the cosmetic composition of the present invention is an ointment, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicon dioxide, talc or zinc oxide can be used as a carrier component. When the preparation of the cosmetic composition of the present invention is a powder or spray, lactose, talc, silicon dioxide, aluminum hydroxide, calcium silicate or polyamide powder can be used as a carrier component, especially, when the preparation of the cosmetic composition of the present invention is a spray, a propellant such as chlorofluorocarbon, propane / butane or dimethyl ether can be contained.

[0047] When the cosmetic composition of the present invention is formulated as a solution or emulsion, a solvent, solubilizer or emulsifier is used as a carrier component, for example, water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol oil, aliphatic glycerol esters, polyethylene glycol or fatty acid esters of sorbitan can be used.

[0048] When the preparation of the cosmetic composition of the present invention is a suspension, a liquid diluent such as water, ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitan ester, polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, tragacanth gum, etc., can be used as a carrier component.

[0049] When the formulation of the cosmetic composition of the present invention is a surfactant-containing cleanser, fatty alcohol sulfates, fatty alcohol ether sulfates, sulfosuccinic acid monoesters, isethionates, imidazolium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamido betaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives, ethoxylated glyceryl fatty acid esters, and the like can be used as carrier components.

[0050] The cosmetic composition of the present invention may contain, in addition to the peptide as an active ingredient and a carrier ingredient, ingredients conventionally used in cosmetic compositions, and may contain conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances.

[0051] According to another aspect of the present invention, there is provided a pharmaceutical composition for treating or preventing a disease caused by particulate matter, the pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

[0052] In one embodiment, the peptide of the present invention may have an activity of inhibiting the activation of the aryl hydrocarbon receptor (AHR). The inhibition of AHR activation by the peptide may be an inhibition of AHR translocation into the cell nucleus.

[0053] In another embodiment, the peptide of the present invention may have an activity of inhibiting cytochrome P450 activity. The inhibition of cytochrome P450 activity by the peptide may be inhibition of the activation or expression of cytochrome P450.

[0054] In another embodiment, the particulate matter may include polycyclic aromatic hydrocarbons (PAHs).

[0055] The term "prevention" refers to inhibiting the occurrence of symptoms of a disease or its complications caused by particulate matter, and the term "treatment" refers to alleviating or eliminating the symptoms of a disease or its complications that have already been caused by particulate matter.

[0056] Diseases caused by particulate matter can be selected from the group consisting of: atopic dermatitis, contact dermatitis, seborrheic dermatitis, acne, dry skin disease, psoriasis; allergic rhinitis, acute bronchitis, chronic bronchitis, emphysema, pulmonary insufficiency, asthma, bronchiectasis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiolitis, acute upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, tonsillitis, laryngitis; dry eyes, allergic conjunctivitis, glaucoma, cataracts, macular degeneration, retinal hemorrhage, retinal detachment, retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy; cancer, immunotoxicity, peripheral nervous system damage, central nervous system damage, endocrine diseases, reproductive organ disorders, infant development disorders, anemia, arrhythmia, heart attack, angina pectoris and myocardial infarction, but are not limited to these.

[0057] The pharmaceutical composition of the present invention comprises: (i) a therapeutically effective amount of the peptide of the present invention; and (ii) a pharmaceutically acceptable carrier.

[0058] The term "therapeutically effective amount" refers to an amount sufficient for the composition of the present invention to achieve the effect of treating or preventing diseases caused by particulate matter.

[0059] Pharmaceutically acceptable carriers are usually used in the preparation of drugs, and examples thereof may include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, mineral oil, etc., but are not limited thereto. A detailed description of suitable pharmaceutically acceptable carriers and preparations is shown in Remington's Pharmaceutical Sciences (1995, 19th edition).

[0060] The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and the like.

[0061] The appropriate dose of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, patient's age, weight, sex, condition, diet, administration time, administration route, excretion rate and reaction sensitivity, and an ordinary skilled physician can easily determine and prescribe the effective dose for the desired treatment or prevention.

[0062] The daily dose of the pharmaceutical composition of the present invention is 0.001 mg / kg to 10,000 mg / kg.

[0063] The pharmaceutical composition of the present invention can be prepared in the form of unit dose by using pharmaceutically acceptable carriers and / or excipients according to methods that can be easily carried out by those skilled in the art to which the present invention belongs, or can be prepared by being included in a multi-dose container. In this case, the preparation can be in the form of a solution, suspension or emulsion in an oil or aqueous medium, or can be in the form of an extract, powder, granule, tablet or capsule, and can additionally include a dispersant or stabilizer.

[0064] Beneficial effects

[0065] The peptide of the present invention has outstanding activity in preventing cell damage caused by particulate matter, and can be used as an active substance to protect skin cells, respiratory cells or corneal cells from the damage of particulate matter. In addition, the peptide of the present invention can be developed as a therapeutic agent for various diseases caused by particulate matter.

[0066] However, the effects of the present invention are not limited to the above-mentioned effects, and other effects not mentioned will be clearly understood by those skilled in the art from the following description. BRIEF DESCRIPTION OF THE DRAWINGS

[0067] Figure 1 is a schematic diagram illustrating the signaling mechanism mediated by the aryl hydrocarbon receptor (AHR).

[0068] Figure 2 The results of Western blot experiments are shown, which show that the increase in AHR nuclear translocation induced by particle treatment in human keratinocytes HaCaT was significantly reduced by treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1.

[0069] Figure 3 The results of the P450 activity assay experiments are shown, which show that:

[0070] Treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 reduced the increase in cytochrome P450 activity induced by particulate matter treatment in human keratinocytes HaCaT in a concentration-dependent manner.

[0071] Figure 4 The results of the P450 activity assay experiments are shown, which show that:

[0072] Treatment with a peptide consisting of the amino acid sequence of SEQ ID NO: 1 reduced the increase in cytochrome P450 activity induced by particulate matter treatment in human alveolar epithelial cells A549 in a concentration-dependent manner. DETAILED DESCRIPTION

[0073] Hereinafter, the present application will be described in detail with reference to examples. The following examples specifically illustrate the present application, but the content of the present application is not limited to the following examples.

[0074] Example

[0075] Preparation Example 1: Preparation of peptide

[0076] The peptides having the amino acid sequence of SEQ ID NO: 1 shown in Table 1 below were synthesized using an automatic peptide synthesizer (Liberty, CEM, USA), and the synthesized peptides were purified by C18 reverse phase high performance liquid chromatography (HPLC) (U-3000, Thermo Fisher Scientific, USA). Pursuit XRs C18 (250*4.65mm Agilent, USA) as the column.

[0077] [Table 1]

[0078] SEQ ID NO Amino acid sequence of peptide 1 SSNAEVLALF

[0079] Experimental Example 1: Nuclear translocation assay of AHR

[0080] Polycyclic aromatic hydrocarbons (PAHs) present in particulate matter act as ligands for AHR, thereby promoting nuclear translocation of AHR when PAHs penetrate into cells and bind to AHR. To confirm the effect of the synthesized peptide in inhibiting cell damage caused by particulate matter, experiments were performed to demonstrate whether the peptide inhibits nuclear translocation of AHR observed upon ligand-AHR binding after treating cells with particulate matter.

[0081] Human keratinocytes HaCaT cells were cultured at 5 x 10 5 The cells were seeded into 6-well plates at a density of 10 cells / well. After overnight culture, the medium was replaced with serum-free medium. The keratinocytes HaCaT were pretreated with the synthetic peptides at each concentration (20 μM, 100 μM, and 200 μM) for 1 hour. Then, 50 μg / cm 2The cells were treated with urban particulate matter (Sigma, NIST1648A) for 1 hour. After collecting keratinocytes, nuclear extracts were prepared and subjected to Western blotting. Western blotting was performed using anti-AHR antibodies (Cell Signaling Technology) according to protocols known in the art.

[0082] As a result of the experiment, Figure 2 The results of the Western blot shown show that the nuclear translocation of AHR in cells treated with particles (NC) increased rapidly compared to control cells not treated with particles (Con). In addition, it was confirmed that the nuclear translocation level of AHR increased by particle treatment was significantly reduced in cells treated with the peptide of the amino acid sequence of SEQ ID NO: 1.

[0083] Experimental Example 2: Analysis of Cytochrome P450 Activity

[0084] When polycyclic aromatic hydrocarbons (PAH) present in particulate matter penetrate into cells and bind to AHR, it promotes nuclear translocation of AHR. It is known that AHR translocated to the nucleus forms a complex AHR / ARNT with the AHR nuclear translocator (ARNT), which acts as a transcription factor to promote the expression of cytochrome P450 (CYP). In order to confirm the effect of the synthesized peptide in inhibiting cell damage caused by particulate matter, an experiment was conducted to confirm whether the peptide inhibits the activity of cytochrome P450 after treating cells with particulate matter.

[0085] First, human keratinocytes HaCaT cells were cultured at 1x 10 4 The cells were seeded into 96-well plates at a density of 10 cells / well. After overnight culture, the medium was replaced with serum-free medium. The keratinocytes HaCaT were pretreated with the synthetic peptides at each concentration (20 μM, 100 μM, and 200 μM) for 1 hour. Then, 50 μg / cm 2 The cells were treated with urban particulate matter (Sigma, NIST1648A) for 24 hours. After the keratinocytes were collected, the P450-Glo TM The activity of cytochrome P450 was measured using an assay kit (Promega).

[0086] As a result of the experiment, Figure 3The results of the measurement of cytochrome P450 activity shown in the figure show that the cytochrome P450 activity in the cells treated with particles (NC) increased rapidly compared to the control cells (Con) not treated with particles. In addition, it was confirmed that the activity of cytochrome P450 increased by the treatment with particles decreased in the cells treated with the peptide of the amino acid sequence of SEQ ID NO: 1. In addition, the increase in cytochrome P450 activity caused by the treatment with particles decreased in a manner dependent on the concentration of the treated peptide when the cells were treated with the peptide.

[0087] In addition, to confirm whether the peptide can inhibit respiratory damage caused by particulate matter, a cytochrome P450 activity assay experiment was performed on human alveolar epithelial cells A549 cells.

[0088] First, human alveolar epithelial A549 cells were cultured at 1.2 x 10 4 The cells were seeded into 96-well plates at a density of 10 cells / well. After overnight culture, the medium was replaced with serum-free medium. Alveolar epithelial A549 cells were pretreated with the synthetic peptides at each concentration (20 μM, 100 μM, and 200 μM) for 1 hour. Then, 50 μg / cm 2 The cells were treated with urban particulate matter (Sigma, NIST1648A) for 24 hours. After the treated cells were collected, the P450-Glo TM The activity of cytochrome P450 was measured using an assay kit (Promega).

[0089] As a result of the experiment, Figure 4 From the results of the measurement of cytochrome P450 activity shown in , it can be seen that the cytochrome P450 activity in the cells treated with particles (NC) increased rapidly compared to the control cells (Con) not treated with particles, and it was confirmed that the cytochrome P450 activity increased by the particle treatment decreased in the cells treated with the peptide of the amino acid sequence of SEQ ID NO: 1. In addition, the increase in cytochrome P450 activity caused by the particle treatment decreased in a manner dependent on the treatment peptide concentration during the peptide treatment.

[0090] Although the representative embodiments of the present application have been exemplarily described, the scope of the present application is not limited to the specific embodiments described above, and those skilled in the art may modify the present application within the scope described in the claims of the present application.

[0091] [Sequence Listing Free Text]

[0092] SEQ ID NO:1:Ser Ser Asn Ala Glu Val Leu Ala Leu Phe <110> kelgan gmbh <120> Peptides with protective activity against cell damage caused by particulate matter and uses thereof <130> 2020-OPA-4696PCT <150> KR 10-2020-0159849 <151> 2020-11-25 <160> 1 <170> KoPatentIn 3.0 <210> 1 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Artificial peptides <400> 1 Ser Ser Asn Ala Glu Val Leu Ala Leu Phe 1 5 10

Claims

1. A peptide consisting of the amino acid sequence of SEQ ID NO:

1.

2. A composition for preventing cell damage caused by particulate matter, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

3. The composition according to claim 2, wherein the cell damage is skin cell damage, respiratory cell damage or corneal cell damage.

4. The composition of claim 2, wherein the particulate matter comprises polycyclic aromatic hydrocarbons (PAHs).

5. A cosmetic composition for preventing skin cell damage caused by particulate matter, comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

6. The cosmetic composition according to claim 5, wherein the composition is used to improve skin aging, increased skin wrinkles, impaired skin elasticity, impaired skin color, hyperpigmentation, chloasma, freckles, dry skin, skin inflammation or psoriasis.

7. The cosmetic composition according to claim 6, wherein the skin inflammation comprises contact dermatitis or atopic dermatitis.

8. The cosmetic composition according to claim 5, wherein the composition has at least one preparation form selected from the group consisting of solutions, suspensions, emulsions, gels, essences, creams, powders, soaps, shampoos, conditioners, masks, surfactant-containing cleansers, oils, liquid foundations, cream foundations, and sprays.

9. The cosmetic composition according to claim 5, wherein the composition has at least one preparation form selected from the group consisting of lotion, cleansing foam, and cleansing water.

10. A pharmaceutical composition for treating or preventing a disease caused by particulate matter, the pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 1 as an active ingredient.

11. The pharmaceutical composition according to claim 10, wherein the disease caused by particulate matter is a disease selected from the group consisting of: atopic dermatitis, contact dermatitis, seborrheic dermatitis, acne, xeroderma, psoriasis; allergic rhinitis, acute bronchitis, chronic bronchitis, emphysema, pulmonary insufficiency, asthma, bronchiectasis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis, acute upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, tonsillitis, laryngitis; dry eyes, allergic conjunctivitis, glaucoma, cataract, macular degeneration, retinal hemorrhage, retinal detachment, retinitis pigmentosa; cancer, immunotoxicity, peripheral nervous system damage, central nervous system damage, endocrine disease, reproductive organ disorder, infant development disorder, anemia, arrhythmia, heart attack, angina pectoris and myocardial infarction.

12. The pharmaceutical composition according to claim 11, wherein the disease caused by particulate matter comprises a disease selected from the group consisting of age-related macular degeneration and diabetic retinopathy.

13. The pharmaceutical composition of claim 10, wherein the particulate matter comprises polycyclic aromatic hydrocarbons (PAH).

14. Use of a peptide consisting of the amino acid sequence of SEQ ID NO: 1 in the preparation of a drug for treating or preventing diseases caused by particulate matter.

15. The use according to claim 14, wherein the disease caused by particulate matter includes a disease selected from the group consisting of: atopic dermatitis, contact dermatitis, seborrheic dermatitis, acne, dry skin disease, psoriasis; allergic rhinitis, acute bronchitis, chronic bronchitis, emphysema, pulmonary insufficiency, asthma, bronchiectasis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis, acute upper respiratory tract infection, pneumonia, sinusitis, pharyngitis, tonsillitis, laryngitis; dry eyes, allergic conjunctivitis, glaucoma, cataract, macular degeneration, retinal hemorrhage, retinal detachment, retinitis pigmentosa; cancer, immunotoxicity, peripheral nervous system damage, central nervous system damage, endocrine disease, reproductive organ disorder, infant development disorder, anemia, arrhythmia, heart attack, angina pectoris and myocardial infarction.

16. The use according to claim 14, wherein the disease caused by particulate matter comprises a disease selected from the group consisting of age-related macular degeneration and diabetic retinopathy.

Images